Mostrar el registro sencillo del ítem

dc.contributor.author
Frecha, Cecilia Ariana  
dc.contributor.author
Levy, C.  
dc.contributor.author
Costa, C.  
dc.contributor.author
Negre, D.  
dc.contributor.author
Amirache, F.  
dc.contributor.author
Buckland, R.  
dc.contributor.author
Russell, S. J.  
dc.contributor.author
Cosset, F. L.  
dc.contributor.author
Verhoeyen, E.  
dc.date.available
2023-03-06T13:38:48Z  
dc.date.issued
2018  
dc.identifier.citation
Quiescent lymphocytes gene transfer with measles virus glycoprotein-pseudotyped lentiviral vectors requires binding to SLAM and CD46 receptors; European Society of Gene and Cell Therapy British Society for Gene Therapy Collaborative Congress; Brighton; Reino Unido; 2011; 1-2  
dc.identifier.uri
http://hdl.handle.net/11336/189655  
dc.description.abstract
Lentiviral transduction of quiescent lymphocytes is key for gene therapy. However, transduction with classical VSVG- pseudotyped LVs needs at least cell cycle entry to occur. We generated lentiviral vectors pseudotyped with measles virus glycoproteins (MV-LVs) that showed to be independent of the cell cycle status therefore allowing efficient and stable trans- duction of G0/G1a T and B cells with the bonus of maintaining their quiescent state. Since MV-LVs recognizes CD46 and SLAM molecules on the target cells? membrane we looked into the roles of each of these receptors on the transduction process. LVs that recognized only SLAM or CD46 receptors did not result in stable transduction of resting lymphocytes. Looking in depth, CD46- tropic vectors accomplished vector-cell binding, fusion, and reverse transcription but no provirus integration while SLAM- tropic vectors were blocked already at the level of fusion. Im- portantly, efficient and stable transduction of quiescent T and B cells only occurred when both CD46 and SLAM binding sites were present in cis in the MV-hemagglutinin envelope glyco- protein. In addition, the way of entry of MV-LVs appears to be crucial for the efficient transduction observed and strongly re- sembles macropinocytosis. Taken together we propose that vec- tor entry and reverse transcription can already occur through CD46 receptor but SLAM binding and signalling is absolutely required to ultimately achieve successful integration and stable transduction of quiescent lymphocytes.  
dc.format
application/pdf  
dc.language.iso
eng  
dc.publisher
Marie Anne Liebert  
dc.rights
info:eu-repo/semantics/restrictedAccess  
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/  
dc.subject
GENE THERAPY  
dc.subject
LENTIVIRAL VECTORS  
dc.subject
MEASLES VIRUS  
dc.subject
QUISCENT CELLS  
dc.subject.classification
Tecnologías que involucran la identificación de ADN, proteínas y enzimas, y cómo influyen en el conjunto de enfermedades y mantenimiento del bienestar  
dc.subject.classification
Biotecnología de la Salud  
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD  
dc.title
Quiescent lymphocytes gene transfer with measles virus glycoprotein-pseudotyped lentiviral vectors requires binding to SLAM and CD46 receptors  
dc.type
info:eu-repo/semantics/publishedVersion  
dc.type
info:eu-repo/semantics/conferenceObject  
dc.type
info:ar-repo/semantics/documento de conferencia  
dc.date.updated
2022-11-09T19:16:34Z  
dc.journal.pagination
1-2  
dc.journal.pais
Estados Unidos  
dc.journal.ciudad
washington  
dc.description.fil
Fil: Frecha, Cecilia Ariana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Medicina Traslacional e Ingeniería Biomédica - Hospital Italiano. Instituto de Medicina Traslacional e Ingeniería Biomédica.- Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional e Ingeniería Biomédica; Argentina  
dc.description.fil
Fil: Levy, C.. Ecole Normale Superieure de Lyon; Francia  
dc.description.fil
Fil: Costa, C.. Ecole Normale Superieure de Lyon; Francia  
dc.description.fil
Fil: Negre, D.. Ecole Normale Superieure de Lyon; Francia  
dc.description.fil
Fil: Amirache, F.. Ecole Normale Superieure de Lyon; Francia  
dc.description.fil
Fil: Buckland, R.. Inserm; Francia  
dc.description.fil
Fil: Russell, S. J.. Mayo Clinic - Minnesota; Estados Unidos  
dc.description.fil
Fil: Cosset, F. L.. Ecole Normale Superieure de Lyon; Francia  
dc.description.fil
Fil: Verhoeyen, E.. Ecole Normale Superieure de Lyon; Francia  
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://www.liebertpub.com/doi/10.1089/hum.2011.2525  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.conicet.rol
Autor  
dc.coverage
Internacional  
dc.type.subtype
Congreso  
dc.description.nombreEvento
European Society of Gene and Cell Therapy British Society for Gene Therapy Collaborative Congress  
dc.date.evento
2011-10-27  
dc.description.ciudadEvento
Brighton  
dc.description.paisEvento
Reino Unido  
dc.type.publicacion
Journal  
dc.description.institucionOrganizadora
European Society for Gene and Cell Therapy  
dc.description.institucionOrganizadora
British Society for Gene Therapy  
dc.source.revista
Human Gene Therapy  
dc.date.eventoHasta
2011-10-31  
dc.type
Congreso